to acquire

							Ranbaxy Laboratories
        Ltd
                  Presented by
              Sudip & Pradipta
            Company Highlights


   Largest pharmaceutical company
   FDA inspected and approved facilities.
   Expertise in diverse categories
   Expertise in OTC
   Strengths and vibrancy
   Other Expertise
                              Timelines
   1962: Ranjit Singh and Gurbux Singh in Amritsar
   1977: First JV Nigeria
   1987: State-of-the-art API facility in Toansa in preparation for entry
          into the U.S. market, receives FDA approval in 1988
   1992: Launches a joint marketing agreement with Eli Lilly
   1993: A joint venture is launched in China; a new research-driven
          NCE and NDDS strategy launched
   1995: The company acquires Ohm Laboratories in the United
          States and builds a new FDA-approved production facility
   2000: Acquires Basics, Bayer's generics business in Germany; the
          company enters Brazil
   2003: Acquires Aventis in France
   Latest: Wish to acquire $2 Billion stake in Merck
Internationalization
              International Biz
    USA
   Largest Healthcare market
   Entered in 1995, now the largest market for the
    company
   Acquire Ohm labs
   28% of Ranbaxy’s revenues
   96 products approved by FDA
     ITALY(GSK) & SPAIN
   Organic opportunities.
   Bought Allen in Italy
   Among top 10 global market.
   Low penetration on generics.
   Patents expiries happen later.
   First movers advantage.
      BELGIUM (Ethimed)

   High priced and profitable market.
   Market is not too large.
   Existence of 10-12 products.
     ROMANIA (Terapia)
   Low cost market in terms of manufacturing.
   Strategically well positioned.
   Wide marketing authorizations.
   Strong product portfolio.
   Strong field force
     Managing the business

 Created trade support & networks overseas
 Confidence in generic drug business
Germany          4.8
UK               2.8
France           1.6
Italy            0.5
(major size of generics market in $ billion)
                   Cont…


 Allowed   to diverse into new markets

 Intangible   assets